PTHL Pheton Holdings Limited: Enterprise Value to EBITDA Ratio

Pheton Holdings (PTHL) - corporate logo

The visual snapshot of EV/EBITDA price action for Pheton Holdings Ltd (PTHL) currently stands at 0.00, coinciding with a lull in the development of new IT therapy solutions. The business relies on the delivery of radiotherapy software, generating moderate revenue from the digitalization of clinics. Meanwhile, Pheton Holdings Ltd (PTHL) is heavily dependent on external contractors, delegating production and research to third-party organizations.

Pheton Holdings - PTHL Business Value to Operating Income Before Depreciation (period 11/23/2025 - 01/16/2026)

Comprehensive metric breakdowns and analytics for Pheton Holdings Limited (PTHL)

- market price and analyst price targets:
- company stock capitalization data:
Fundamental valuation:Pheton Holdings PTHL
Original product of Pheton Holdings

The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before depreciation and interest, allowing for an assessment of a company's actual ability to generate cash flow regardless of its debt load. By analyzing the EV/EBITDA chart trend of Pheton Holdings Ltd (PTHL), an investor can gauge the financial stability of Pheton Holdings Ltd (PTHL) in the implementation of high-tech solutions for Chinese oncology and brachytherapy.

Key competitors

Haleon Group - Enterprise Value to EBITDA Ratio|Kenvue (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|Jyong Biotech - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals Inc - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company PLC) - EV/EBITDA Multiple|Company Value to EBITDA alvotech.com ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia (LQDA)|GLPG (Galapagos) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals Inc)|MNKD - Enterprise Value to EBITDA Ratio|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PCRX - EV/EBITDA Multiple|ARS Pharmaceuticals Inc (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Theravance Biopharma Inc (TBPH)|AQST (aquestive.com) - EV/EBITDA Multiple|SCPH: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tectonic Therapeutic, Inc. (TECX)|Tonix Pharmaceuticals Holding Corp. - Enterprise Value to Operating Income Before Depreciation|China SXT Pharmaceuticals - Enterprise Value to EBITDA Ratio|EPRX: Enterprise Value to Operating Income Before Depreciation|BHST: Enterprise Value to EBITDA Ratio|Company Value to EBITDA Invizyne|Oramed Pharmaceuticals Inc. (ORMP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ENTX (Entera Bio Ltd) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio HYFT|ABVC BioPharma, Inc. - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CPIX|Total Company Value to Operating Income Before Depreciation Ratio Quantum BioPharma Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FibroGen FGEN|EV/EBITDA Multiple telomirpharma.com TELO|Rani Therapeutics Inc - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation SNYR (synergychc.com)|Rallybio (RLYB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Lexaria Bioscience Corp|Enterprise Value to EBITDA Ratio PULM|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization APM|EV/EBITDA Multiple LYRA|EV/EBITDA Multiple Impact BioMedical, Inc. (IBO)|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals)|Business Value to Operating Income Before Depreciation YCBD|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CYTO - EV/EBITDA Multiple|LIPO (Lipella Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio OPTN (OptiNose)|PIRS (Pieris Pharma) - EV/EBITDA Multiple|Procaps Group Corp - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PTPI|qlsyy.net (QLI) - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ACELYRIN SLRN|TFFP (TFF Pharmaceuticals, Inc.) - Company Value to Operating Income Before Depreciation Ratio